MARKET

IMDX

IMDX

Insight Molecular Diagnostics Inc.
NASDAQ
3.920
-0.030
-0.76%
After Hours: 3.920 0 0.00% 19:30 09/25 EDT
OPEN
3.990
PREV CLOSE
3.950
HIGH
4.002
LOW
3.760
VOLUME
313.50K
TURNOVER
--
52 WEEK HIGH
8.51
52 WEEK LOW
2.420
MARKET CAP
128.28M
P/E (TTM)
-2.6397
1D
5D
1M
3M
1Y
5Y
1D
Insight Molecular Diagnostics Revises Chronix Royalty Agreement Terms
TipRanks · 5d ago
iMDx Amends Chronix Merger Agreement, Replacing Ongoing 10% CNI Monitor Royalty With 10% Sale Payment Upon CNI Monitor Sale
Benzinga · 5d ago
Weekly Report: what happened at IMDX last week (0914-0918)?
Weekly Report · 5d ago
Weekly Report: what happened at IMDX last week (0907-0911)?
Weekly Report · 09/14 10:31
Weekly Report: what happened at IMDX last week (0831-0904)?
Weekly Report · 09/07 10:24
Weekly Report: what happened at IMDX last week (0824-0828)?
Weekly Report · 08/31 10:32
Insight Molecular Diagn Price Target Announced at $8.00/Share by LUCID CAPITAL MARKETS
Dow Jones · 08/24 15:00
Insight Molecular Diagn Initiated at Buy by LUCID CAPITAL MARKETS
Dow Jones · 08/24 15:00
More
About IMDX
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

Webull offers Insight Molecular Diagnostics Inc stock information, including NASDAQ: IMDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMDX stock methods without spending real money on the virtual paper trading platform.